

REGISTERED COMPANY NUMBER: 06996068 (England and Wales)
REGISTERED CHARITY NUMBER: 1132984

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2020
FOR
THE INTERNATIONAL CML FOUNDATION**

Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

THE INTERNATIONAL CML FOUNDATION

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2020**

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance Sheet	8
Notes to the Financial Statements	9 to 17

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2020**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

Significant activities

In furtherance of the objects, the Foundation has the following powers:-

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

Public benefit

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2020**

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The 2019/2020-year for the iCMLf can clearly be separated into pre and post pandemic activities. September to December 2019 saw the conclusion of the fundraising activity where 26 members of the iCMLf climbed Mount Kilimanjaro and raised over \$300,000 for the iCMLf cure programs. While in Africa we hosted the first iCMLf education symposium on the continent, which was closely followed by the iCMLf Forum for physicians from emerging regions in the USA. 10 physicians finalized their preceptorships and 20 more were accepted into the 2020 program.

In February 2020 it became clear that the pandemic was going to fundamentally change the activities, programs and funding of the Foundation. We halted all travel for the preceptors and the program is on hiatus for the foreseeable future.

Given lack of knowledge and concern for patient's vulnerability, the experts treating CML started to share experiences and ideas. This international collaboration began organically and it quickly became clear that the iCMLf was ideally positioned to coordinate this effort. As case collection expanded and formalised, we formed the iCMLf CANDID (Cml AND covID) study. The primary aim of this study is to collect emerging clinical data on CML patients infected with the SARS-CoV-2 virus as rapidly as possible. To date 202 cases have been collected and an abstract accepted for presentation at the American Society of Hematology meeting in December 2020.

As information changed and the pandemic worsened the Foundation initiated key activities to provide guidance and reassurance to both physicians and their CML patients alike. The online COVID-19 hub hosts expert statements, frequently asked questions, relevant clinical papers and other reliable resources. Launched in April 2020 the Hub has had 28,000 views to the 31st August.

The iCMLf hosted live webinars with CML experts, on how to manage patients with CML during the COVID-19 pandemic. Commencing in May 2020, by 31st August 5 webinars had 400 participants and 1,300 views once available online.

Online Education Services

WWW.CML-FOUNDATION.ORG

The iCMLf website has always been one of the key worldwide educational online resources for CML. In 2019/20 there were more than 25,000 visitors and 63,000 page visits. A 54% increase on 2018/2019.

Visitors were from 166 different countries and 71 % of these are low and middle-income countries.

Most visited pages focused on COVID-19 this year with the 3 highest viewed pages being; 1) Advice for people with CML and COVID-19, 2) Case Discussion Forum, 3) COVID-19 Hub.

Virtual Education Programme

19 new education modules were added in 2019/20.

There were 4,890 presentations viewed in the year. A 385 increase on 2018/19.

Clinical Case Discussion Forum

This saw more than 8,340 case views during 2019/20. A 15% increase on 2018/19

COVID-19 Hub - New program April to August 2020

Advice and information for people with CML and COVID-19 with 28,000 views to date.

iCMLf Conversations - New program May to August 2020

The iCMLf hosted 5 live webinars with CML experts. Over 400 participants and more than 1,300 views on-demand to date.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2020**

Preceptorships

The iCMLf Clinical Preceptorship Program continues to improve the knowledge and skills of physicians treating CML in emerging economic regions through individually tailored observerships. During their 3-4 week intensive program, participants are involved in outpatient clinics, haematology ward rounds, seminars, discussion forums and laboratory work to arm them with a practical understanding of the most up-to-date protocols and guidelines to treat CML. One of the most valued benefits continues to be the close contacts and networks established during their time at the centre which continue to support their needs even after they have returned home.

From 1st September 2019 to 31st December 2019 10 physicians from emerging regions took part in the program. In January 2020 a further 20 preceptors were accepted into the program with 11 confirmed dates and 2 incurring travel costs.

Fundraising activities

The fundraising activity is a large component of the Chief Executive's travel to the scientific meetings as these are where future funding with potential donors is discussed.

In 2019/2020 our major public fundraising activity was preparation for the iCMLf climb for a cure in October 2019. A team of 26 people climbed Mount Kilimanjaro and raised \$305,000 in total (2018-2020)

Funds raised in 2019 from the annual John Goldman Fun Run also supported the iCMLf Climb for a Cure.

FINANCIAL REVIEW

Financial position

The financial position of the International CML Foundation remains solid.

Principal funding sources

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website. In 2019/2020 funds were raised through the fundraising adventure the iCMLf Climb for a Cure and on the annual John Goldman Fun Run.

Reserves policy

The reserves at the year end were £383,014 (2019 - £409,720). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

FUTURE PLANS

While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.

The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues and vaccines become available.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2020**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

Organisational structure

The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.

The operational team; Communications Director, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.

Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September each year. Further directors planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.

The operational team meets every 6-8 weeks. The editor and chief executive meet biweekly and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

06996068 (England and Wales)

Registered Charity number

1132984

Registered office

20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

Trustees

Professor T P Hughes Professor
Professor M Baccarani Professor
Professor J Cortes Professor
Professor B Druker Professor
Professor A Hochhaus Professor
Professor J Radich Professor
Professor C Schiffer Professor
Professor J F Apperley DM FRCP/Path Professor
Professor M Mauro Professor
Professor G Saglio Professor

Company Secretary

Ms N C Evans

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2020**

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner


R Appleyard FCA
ICAEW
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

Bankers

HSBC Bank, 152 Portobello Road, London, W11 2EA

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 9th June 2021 and signed on its behalf by:



Professor T P Hughes - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

Independent examiner's report to the trustees of The International CML Foundation ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2020.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

R Appleyard FCA
ICAEW
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

15th June 2021

THE INTERNATIONAL CML FOUNDATION

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31ST AUGUST 2020**

	Notes	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		65,872	156,392	222,264	376,919
Other income	2	(21,893)	-	(21,893)	1,387
Total		43,979	156,392	200,371	378,306
EXPENDITURE ON					
Charitable activities					
Preceptorships		532	36,160	36,692	99,253
Diagnosis & testing		-	1,035	1,035	19,347
Virtual Education Program		531	30,067	30,598	52,117
Scientific meetings					
		9,183	4,960	14,143	17,000
ICMLF Forum		30,370	-	30,370	44,946
Clinical forum		-	-	-	2,192
Communications		533	31,403	31,936	29,719
Fundraising		533	20,948	21,481	34,184
Cure C		533	4,783	5,316	6,355
Candid		35,998	-	35,998	-
Other		19,718	-	19,718	18,781
Total		97,931	129,356	227,287	323,894
NET INCOME/(EXPENDITURE)		(53,952)	27,036	(26,916)	54,412
RECONCILIATION OF FUNDS					
Total funds brought forward		281,986	127,734	409,720	355,308
TOTAL FUNDS CARRIED FORWARD		228,034	154,770	382,804	409,720

The notes form part of these financial statements

THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**BALANCE SHEET
31ST AUGUST 2020**

	Notes	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
CURRENT ASSETS					
Debtors	10	92,949	-	92,949	52,214
Cash at bank and in hand		139,255	154,771	294,026	361,466
		232,204	154,771	386,975	413,680
CREDITORS					
Amounts falling due within one year	11	(4,171)	-	(4,171)	(3,960)
NET CURRENT ASSETS		228,033	154,771	382,804	409,720
TOTAL ASSETS LESS CURRENT LIABILITIES		228,033	154,771	382,804	409,720
NET ASSETS		228,033	154,771	382,804	409,720
FUNDS	12				
Unrestricted funds				228,033	281,986
Restricted funds				154,771	127,734
TOTAL FUNDS				382,804	409,720

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 9th June 2021 and were signed on its behalf by:



T P Hughes - Trustee

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2020**

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- - any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Debtors

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

THE INTERNATIONAL CML FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

1. ACCOUNTING POLICIES - continued

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

2. OTHER INCOME

Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

3. GRANTS PAYABLE

	2020 £	2019 £
Preceptorships	23,963	76,623
Diagnosis & testing	1,035	9,457
	24,998	86,080

4. SUPPORT COSTS

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	16,252	1,536	1,930	-	19,718
Preceptorships	12,197	-	-	532	12,729
Virtual Education Program	28,198	-	-	532	28,730
Scientific meetings	3,611	-	-	532	4,143
ICMLF Forum	5,690	-	-	532	6,222
Communications	22,523	-	-	533	23,056
Fundraising	9,029	-	-	533	9,562
Cure C	4,514	-	-	533	5,047
Candid	35,398	-	-	533	35,931
	137,412	1,536	1,930	4,260	145,138

THE INTERNATIONAL CML FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

4. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

Management fees

		Other resources expended £	Preceptorships £	Virtual Education Program £	
Management & admin		<u><u>16,252</u></u>	<u><u>12,197</u></u>	<u><u>28,198</u></u>	
	Scientific meetings	ICMLF Forum	Communications	Fundraising	
Management & admin	<u><u>£ 3,611</u></u>	<u><u>£ 5,690</u></u>	<u><u>£ 22,523</u></u>	<u><u>£ 9,029</u></u>	
	Cure C £	Candid £	2020 Total activities £	2019 Total activities £	
Management & admin	<u><u>4,514</u></u>	<u><u>35,398</u></u>	<u><u>137,412</u></u>	<u><u>125,954</u></u>	
Finance					
			2020 Other resources expended £	2019 Total activities £	
Bank charges			<u><u>1,536</u></u>	<u><u>1,841</u></u>	
Other					
			2020 Other resources expended £	2019 Total activities £	
Sundry office costs			<u><u>1,930</u></u>	<u><u>1,809</u></u>	
Governance costs					
	Preceptorships	Virtual Education Program	Scientific meetings	ICMLF Forum	Communications
	£	£	£	£	£
Accountancy - Independent examination fee	<u><u>532</u></u>	<u><u>532</u></u>	<u><u>532</u></u>	<u><u>532</u></u>	<u><u>533</u></u>

THE INTERNATIONAL CML FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

4. SUPPORT COSTS - continued

Governance costs - continued

	Fundraising £	Cure C £	Candid £	2020 Total activities £	2019 Total activities £
Accountancy - Independent examination fee	<u>533</u>	<u>533</u>	<u>533</u>	<u>4,260</u>	<u>4,320</u>

5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2020 £	2019 £
Accountancy - Independent examination fee	<u>4,260</u>	<u>4,320</u>

6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st August 2020 nor for the year ended 31st August 2019.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31st August 2020 nor for the year ended 31st August 2019.

7. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2020	2019
Charitable activities	<u>3</u>	<u>3</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2020	2019
£80,001 - £90,000	-	1
£90,001 - £100,000	<u>1</u>	-
	<u>1</u>	<u>1</u>

THE INTERNATIONAL CML FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	144,635	232,284	376,919
Other income	1,387	-	1,387
Total	146,022	232,284	378,306
EXPENDITURE ON			
Charitable activities			
Preceptorships	99,253	-	99,253
Diagnosis & testing	480	18,867	19,347
Virtual Education Program	6,464	45,653	52,117
Scientific meetings	17,000	-	17,000
ICMLF Forum	34,155	10,791	44,946
Clinical forum	2,192	-	2,192
Communications	480	29,239	29,719
Fundraising	34,184	-	34,184
Cure C	6,355	-	6,355
Other	18,781	-	18,781
Total	219,344	104,550	323,894
NET INCOME/(EXPENDITURE)	(73,322)	127,734	54,412
RECONCILIATION OF FUNDS			
Total funds brought forward	355,308	-	355,308
TOTAL FUNDS CARRIED FORWARD	281,986	127,734	409,720

9. VOLUNTEERS

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

THE INTERNATIONAL CML FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2020**

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Other debtors	<u>92,949</u>	<u>52,214</u>

Included within other debtors is a balance of £84,202 in respect of funds held by Paypal. As a result of a change of personnel, the account access is being transferred by Paypal, and until this process has been completed the charity cannot transfer or use these funds.

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Accrued expenses	<u>4,171</u>	<u>3,960</u>

12. MOVEMENT IN FUNDS

	At 1/9/19 £	Net movement in funds £	At 31/8/20 £
Unrestricted funds			
General fund	281,986	(57,868)	224,118
Cepheid	-	3,915	3,915
	281,986	(53,953)	228,033
Restricted funds			
Bristol-Myers Squibb	680	(680)	-
Novartis Pharmaceuticals Corporation	124,445	(1,035)	123,410
Takeda Oncology	2,609	(2,609)	-
Pfizer	-	23,118	23,118
Novartis Killi Climb	-	8,243	8,243
	127,734	27,037	154,771
TOTAL FUNDS	<u>409,720</u>	<u>(26,916)</u>	<u>382,804</u>

THE INTERNATIONAL CML FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	40,064	(97,932)	(57,868)
Cepheid	3,915	-	3,915
	<u>43,979</u>	<u>(97,932)</u>	<u>(53,953)</u>
Restricted funds			
Bristol-Myers Squibb	-	(680)	(680)
Novartis Pharmaceuticals Corporation	-	(1,035)	(1,035)
Takeda Oncology	-	(2,609)	(2,609)
Pfizer	117,458	(94,340)	23,118
Novartis Killi Climb	26,144	(17,901)	8,243
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
	<u>156,392</u>	<u>(129,355)</u>	<u>27,037</u>
TOTAL FUNDS	<u><u>200,371</u></u>	<u><u>(227,287)</u></u>	<u><u>(26,916)</u></u>

Comparatives for movement in funds

	At 1/9/18 £	Net movement in funds £	At 31/8/19 £
Unrestricted funds			
General fund	355,308	(73,322)	281,986
Restricted funds			
Bristol-Myers Squibb	-	680	680
Novartis Pharmaceuticals Corporation	-	124,445	124,445
Takeda Oncology	-	2,609	2,609
	<u>-</u>	<u>127,734</u>	<u>127,734</u>
TOTAL FUNDS	<u><u>355,308</u></u>	<u><u>54,412</u></u>	<u><u>409,720</u></u>

THE INTERNATIONAL CML FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2020**

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	146,022	(219,344)	(73,322)
Restricted funds			
Incyte	31,847	(31,847)	-
Bristol-Myers Squibb	25,277	(24,597)	680
Novartis Pharmaceuticals Corporation	143,312	(18,867)	124,445
Takeda Oncology	31,848	(29,239)	2,609
	<u>232,284</u>	<u>(104,550)</u>	<u>127,734</u>
TOTAL FUNDS	<u>378,306</u>	<u>(323,894)</u>	<u>54,412</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/18 £	Net movement in funds £	At 31/8/20 £
Unrestricted funds			
General fund	355,308	(131,190)	224,118
Cepheid	-	3,915	3,915
	<u>355,308</u>	<u>(127,275)</u>	<u>228,033</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	-	123,410	123,410
Pfizer	-	23,118	23,118
Novartis Killi Climb	-	8,243	8,243
	<u>-</u>	<u>154,771</u>	<u>154,771</u>
TOTAL FUNDS	<u>355,308</u>	<u>27,496</u>	<u>382,804</u>

THE INTERNATIONAL CML FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	186,086	(317,276)	(131,190)
Cepheid	3,915	-	3,915
	<u>190,001</u>	<u>(317,276)</u>	<u>(127,275)</u>
Restricted funds			
Incyte	31,847	(31,847)	-
Bristol-Myers Squibb	25,277	(25,277)	-
Novartis Pharmaceuticals Corporation	143,312	(19,902)	123,410
Takeda Oncology	31,848	(31,848)	-
Pfizer	117,458	(94,340)	23,118
Novartis Killi Climb	26,144	(17,901)	8,243
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
	<u>388,676</u>	<u>(233,905)</u>	<u>154,771</u>
TOTAL FUNDS	<u>578,677</u>	<u>(551,181)</u>	<u>27,496</u>

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st August 2020.